Middlekauff W Bradford's Stock Disposal Following Tourmaline Bio Merger

On October 28, 2025, Middlekauff W Bradford, the Chief Business Officer, General Counsel, and Secretary of Tourmaline Bio, Inc., disposed of 60,988 shares of common stock and 82,213 shares of common stock, leaving him with no shares post-transaction. Additionally, he disposed of employee stock options for 124,991, 46,774, and 58,000 shares of common stock. These transactions were part of the merger agreement between Tourmaline Bio, Inc., Novartis AG, and Torino Merger Sub Inc., where each share was tendered for $48.00 in cash. The stock options were canceled and converted into cash based on the merger consideration.